SCHEMBL14065341

SCHEMBL14065341

COc1ccc(C(O)c2ccccc2)cn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.51
ALDH1A1 P00352 2/20 0.51
POLB P06746 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.49
CHRNA7 P36544 1/20 0.45
MEN1 O00255 2/20 0.41
NNMT P40261 1/20 0.41
CNR2 P34972 1/20 0.41
NPC1 O15118 3/20 0.40
RAB9A P51151 2/20 0.40
OXTR P30559 1/20 0.40
HSD17B1 P14061 1/20 0.40
HSD17B2 P37059 1/20 0.40
ATM Q13315 1/20 0.39
KDM4E B2RXH2 1/20 0.39
LMNA P02545 2/20 0.39
PABPC1 P11940 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ADRB3 P13945 1/20 0.39
HRH1 P35367 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18228247 0.91 NNMT (0.47) KMT2AALDH1A1POLBCHRNA7MEN1
SCHEMBL10365248 0.85 SMN1; SMN2 (0.57) KMT2AALDH1A1POLBSMN1; SMN2LMNA
SCHEMBL4584655 0.85 NPC1 (0.44) KMT2AALDH1A1POLBSMN1; SMN2CHRNA7
SCHEMBL7282322 0.82 SMN1; SMN2 (0.45) KMT2AALDH1A1POLBSMN1; SMN2CHRNA7
SCHEMBL1879755 0.81 ALDH1A1 (0.41) KMT2AALDH1A1POLBCHRNA7NNMT
SCHEMBL3180698 0.79 MEN1 (0.56) KMT2AALDH1A1POLBMEN1NNMT
SCHEMBL1581887 0.78 NNMT (0.46) KMT2AALDH1A1POLBCHRNA7MEN1
SCHEMBL30108570 0.78 NNMT (0.46) KMT2AALDH1A1POLBCHRNA7MEN1
SCHEMBL14511065 0.77 SMN1; SMN2 (0.58) ALDH1A1SMN1; SMN2KDM4ELMNACYP17A1
SCHEMBL10318613 0.76 NPSR1 (0.49) KMT2AALDH1A1POLBCHRNA7MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015175845-A1 BENZIMIDAZOLE DERIVATIVES AND USES THEREOF PELOTON THERAPEUTICS, INC. (US) 2015-11-19 WO disclosed
US-20150225399-A1 HIV INTEGRASE INHIBITORS VIIV HEALTHCARE CO (US) 2015-08-13 US disclosed
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS SHIONOGI & CO., LTD. (JP) 2014-09-11 US disclosed
US-8691991-B2 2-oxonaphthyridine-3-carboxamides HIV integrase inhibitors SHIONOGI & CO., LTD. (JP) 2014-04-08 US disclosed
US-20080234231-A1 Hiv Integrase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-09-25 US disclosed
US-20080214527-A1 Hiv Integrase Inhibitors SHIONOGI & CO. LTD (JP) 2008-09-04 US disclosed
US-20080214503-A1 Hiv Integrase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-09-04 US disclosed
US-20080194523-A1 Hiv Integrase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-08-14 US disclosed
US-20070124152-A1 Hiv Integrase Inhibitors GLAXOSMITHKLINE LLC 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS BCDIN3D, DUT, SAMHD1 KMT2A 502/4885ALDH1A1 3812/4885POLB 113/4885
US-20080214527-A1 Hiv Integrase Inhibitors API5, ING2, SAMHD1 KMT2A 682/4885ALDH1A1 2874/4885POLB 117/4885
US-20150225399-A1 HIV INTEGRASE INHIBITORS ING2, API5, SAMHD1 KMT2A 819/4885ALDH1A1 3073/4885POLB 115/4885
US-20080214503-A1 Hiv Integrase Inhibitors SAMHD1, ACIN1, API5 KMT2A 1762/4885ALDH1A1 3374/4885POLB 27/4885
US-20080194523-A1 Hiv Integrase Inhibitors ING2, API5, SAMHD1 KMT2A 816/4885ALDH1A1 3012/4885POLB 136/4885
US-20080234231-A1 Hiv Integrase Inhibitors ING2, API5, SAMHD1 KMT2A 816/4885ALDH1A1 3012/4885POLB 136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.